Literature DB >> 18331250

Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.

M Bortolami1, A Kotsafti, R Cardin, F Farinati.   

Abstract

The Fas / Fas-ligand (FasL) system is an important death signal pathway in the liver. An enhanced local inflammatory response prompted by FasL expression, which contributes to neutrophil recruitment and interleukin-1 beta (IL-1beta) release, seems to be crucial to chronic liver damage, persistence of viral infections, and probably initiation and / or promotion of HCC. In order to evaluate the expression of Fas, FasL, and IL-1beta in different stages of human liver disease and to determine whether hepatitis B virus (HBV) and hepatitis C virus (HCV) infections modulate their expression, also in relation to apoptosis, we examined 87 liver samples obtained from patients with: chronic hepatitis (CH) (n.42), cirrhosis (n.9) and hepatocellular carcinoma (HCC) (n.16) and corresponding peritumoural tissues (n.16); histologically-normal liver (n.4) as controls. Fas, FasL and IL-1beta mRNA were quantified using reverse transcriptase-polymerase chain reaction. The apoptotic index was evaluated by TUNEL analysis. Our data showed a progressive Fas / FasL increase from CH to cirrhosis followed by a decline from the latter to HCC. In histological sections apoptosis was detected in HCC. A significant difference emerged between HCV and HBV-related disease for IL-1beta expression only in CH. A significant positive correlation between IL-1beta and FasL in HCV-related disease (P = 0.014) and an inverse correlation between IL-1beta and Fas in HBV-related disease (P = 0.021) were observed. The different pattern of IL-1beta, Fas and FasL expression found in HCV- and HBV-mediated liver disease, points to a different modulation of immune response B and C virus induced, while the decline in Fas / FasL expression in HCC may be related to defence mechanisms adopted by HCC cells against the immune system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18331250     DOI: 10.1111/j.1365-2893.2008.00974.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  30 in total

Review 1.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

2.  Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation.

Authors:  Vijay Subramanian; Anil B Seetharam; Neeta Vachharajani; Venkataswarup Tiriveedhi; Nataraju Angaswamy; Sabarinathan Ramachandran; Jeffrey S Crippin; Surendra Shenoy; William C Chapman; Thalachallour Mohanakumar; Christopher D Anderson
Journal:  Transplantation       Date:  2011-12-15       Impact factor: 4.939

3.  Mouse Hepatitis Virus Infection Induces a Toll-Like Receptor 2-Dependent Activation of Inflammatory Functions in Liver Sinusoidal Endothelial Cells during Acute Hepatitis.

Authors:  Christian Bleau; Aveline Filliol; Michel Samson; Lucie Lamontagne
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

4.  Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.

Authors:  M Guzmán-Fulgencio; J Berenguer; M García-Álvarez; D Micheloud; J C López; J Cosín; I Fernández de Castro; P Catalán; P Miralles; S Resino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-03-26       Impact factor: 3.267

5.  Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis.

Authors:  H I Basha; V Subramanian; A Seetharam; D S Nath; S Ramachandran; C D Anderson; S Shenoy; W C Chapman; J S Crippin; T Mohanakumar
Journal:  Am J Transplant       Date:  2011-04       Impact factor: 8.086

6.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

7.  Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosis.

Authors:  Brian B Borg; Anil Seetharam; Vijay Subramanian; Haseeb Ilias Basha; Mauricio Lisker-Melman; Kevin Korenblat; Christopher D Anderson; Surendra Shenoy; William C Chapman; Jeffrey S Crippin; Thalachallour Mohanakumar
Journal:  Liver Transpl       Date:  2011-07       Impact factor: 5.799

8.  Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection.

Authors:  Henry Radziewicz; Chris C Ibegbu; Huiming Hon; Melissa K Osborn; Kamil Obideen; Mohammad Wehbi; Gordon J Freeman; Jeffrey L Lennox; Kimberly A Workowski; Holly L Hanson; Arash Grakoui
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Bax inhibitor-1 down-regulation in the progression of chronic liver diseases.

Authors:  Andromachi Kotsafti; Fabio Farinati; Romilda Cardin; Patrizia Burra; Marina Bortolami
Journal:  BMC Gastroenterol       Date:  2010-04-01       Impact factor: 3.067

10.  TGF-beta1 gene silencing for treating liver fibrosis.

Authors:  Kun Cheng; Ningning Yang; Ram I Mahato
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.